Membership stacking spreads: the advertised price is increasingly not the price
Several programmes now split the charge into medication plus a mandatory platform fee.
Several programmes now split the charge into medication plus a mandatory platform fee.
For context: across 32 tracked tirzepatide telehealth programmes, 17 publish a price we could capture, and the cheapest verified all-in cost is $215 a month at a 10 mg maintenance dose — about $2,580 for a first year. Compounded preparations are not FDA-approved. Prices captured 2026-08-05.
All-in monthly cost at 10 mg
An increasing share of programmes bill medication and a mandatory membership separately, so a table quoting the medication figure alone understates them by the full fee, permanently.
Ask one question before enrolling anywhere: what will I pay in total in month six at 10 mg, including every fee. A programme that cannot answer in a sentence has a structure worth reading carefully.
What this changes for what you pay
Most developments in this category move one of three things: the price of the branded product, which programmes are operating, or what may lawfully be compounded. Very few change the prescription requirement, the pharmacy licensing framework or the clinical review behind a prescription.
The cheapest verified compounded route we track currently sits at $215 a month all-in at a 10 mg maintenance dose, about $2,580 for a first year. Where a development moves that figure, our tables move with it on the next build.
How to verify this yourself
Regulatory claims should be checked against the agency rather than against coverage of the agency. FDA publishes warning letters searchable by company name, a shortage database, and its compounding pages. Trial claims should be checked against the registry entry rather than a press release.
Every source behind this item is linked below, and where a story is still moving we say so rather than implying it is settled.
How to read a pricing story in this market
Pricing stories are the fastest-moving and worst-reported in this category. A figure quoted without a date and a dose is not a price, and most coverage supplies neither.
The specific failure to watch for is a promotional or prepaid rate presented as a standing monthly figure. It understates a year by hundreds of dollars and it is the single most common error we correct.
What this does not change
The prescription requirement, the licensing framework behind a dispensing pharmacy, and the clinical review that should sit in front of any prescription. Those are stable and none of the developments we track has altered them.
It also does not change the arithmetic of choosing a programme: price the dose you expect to hold, add every recurring fee, and verify the pharmacy. The cheapest verified route we track is NexLife at $215 a month all-in at a maintenance dose, about $2,580 for a first year.
Where a development does move those figures, the tables regenerate from the dataset on the next build rather than being edited by hand.
When urgency is the product
Regulatory and market news is routinely used as a sales device. A programme citing a rule change to push you into a twelve-month prepayment is using a real fact to manufacture a deadline that does not apply to you.
The test is simple: does the development change what you can lawfully be prescribed this month? Almost never. Does it change what you should pay? Sometimes. Does it require you to decide today? Essentially never — and a programme insisting otherwise has told you how it treats its patients under commercial pressure.
Putting pricing in proportion
It is one input into a decision with three parts: what you pay at the dose you hold, who makes what you inject, and what happens if you stop. Weighting any one to the exclusion of the others is how people end up on a cheap programme they abandon in month nine.
The frame: 17 programmes publish a price we could capture, spanning $215 to $548 a month all-in at a maintenance dose. Against a spread that wide, most optimisation attempted at the margins is worth less than getting the basis right once.
What good looks like
A programme that states a figure at a named dose, names the pharmacy behind it, publishes cancellation terms before payment, and says plainly that a compounded preparation is not FDA-approved. Four things, all cheap to publish, and a minority of the market does all four.
The cheapest verified route sits at $215 a month all-in, which establishes that disclosure and low price are not in tension. Programmes publishing more are not systematically dearer — which undercuts the usual explanation for withholding.
What to do next
Narrow to two or three on the criterion that actually binds for you, open the individual reviews, and send each the same five questions: total at 10 mg including every fee, which pharmacy, is the prescriber licensed in my state, what notice to cancel, and what is refundable.
Whoever answers all five in writing has told you more than any comparison table can, this one included. Whoever does not has also told you something.
The failure mode this section is guarding against
Choosing a programme on a number that describes a different situation than yours. An entry price when you will hold maintenance. A medication figure when a membership applies. A promotional rate when you will renew. A prepaid rate when you will pay monthly.
Each of those errors is small individually and they compound in the same direction, which is why the cheapest-looking option in most published comparisons is the one most likely to be mis-stated.
Priced correctly, the cheapest verified route sits at $215 a month all-in at a maintenance dose. Anything materially below that band deserves the question of which distortion is producing it.
Why we publish the working rather than a verdict
A single recommendation is more useful to read and less useful to act on, because it hides the weighting. Two readers with different maintenance doses, different coverage and different tolerance for commitment should not receive the same answer.
So the tables carry the inputs and the rankings state their sort key. If you disagree with our weighting, take the file and weight it differently — that is what publishing it is for.
What would make this page wrong
A price change we have not captured, a programme leaving the market, or a figure we recorded from a third party that does not survive checking. All three have happened during 2026 and all three are logged when they do.
Prices here were captured 2026-08-05. Treat anything older than a month as needing a re-check against the provider's own page, which every programme record links directly.
Open these rather than taking our word for it. Every one is a regulator, a trial registry, a label, an accreditor or the manufacturer.
Compare every programme on one screen
The matrix carries all-in price at every dose, fee structure, commitment terms, pharmacy disclosure and verification status for every programme we track.